The National Institutes of Health is sunsetting its influential COVID-19 treatment guidelines, used by millions of doctors to guide care during the pandemic.

Flu and COVID-19 infections have been increasing for weeks across the U.S., and health officials predict infections will continue to grow. 

How do I stay safe now that the public health emergency is over? We answer questions on boosters, risks when flying — and the new JN.1 variant.

Now that official COVID emergency declarations have ended, how should people evaluate their risk of SARS-CoV-2? That's the subject of our frequently asked questions offering.

The drug is the most effective way to cut the risk of severe disease. It's heading to China now. Yet the drug is underused in some places. Why? And are there options if you're not a good candidate?

Biden's physician says the president's symptoms "continue to improve significantly" and that he is now mainly dealing with a sore throat.

Paxlovid has been highly effective at reducing the risks of hospitalization and death, but some patients report a "Paxlovid rebound" in which the disease returns.

Some people have had trouble getting Paxlovid pills quickly, despite the administration's effort to ease access after a COVID test confirms infection.

The antiviral pill is available to patients older than 12 who have tested positive for COVID and are at risk for developing a severe case of the disease.

States and health providers report they've dispensed less than half their supply from the government, raising fears that the drugs may go to waste while people who could benefit get sicker.

The Biden administration's new program enables high-risk patients who test positive to get antiviral pills on the spot in some pharmacies. But many pharmacies won't be able to participate.

The antiviral pill molnupiravir was authorized and distributed by the government late last year. But it's not doctors' first choice of treatment, except for a narrow slice of patients.

NPR has obtained the government's $5.3 billion contract for the first 10 million courses of Paxlovid, an antiviral pill for COVID-19. Here's what's in it.

Paxlovid and molnupiravir have been authorized for emergency use to keep COVID-19 patients out of the hospital, but don't expect to be able to go to your usual pharmacy and get them.

In a highly anticipated decision, the Food and Drug Administration authorized Pfizer's Paxlovid as the first antiviral pill to treat COVID-19 at home.